Anti-ZSCAN16 polyclonal antibody

Objectives: Extracapsular spread (ECS) is an important prognostic factor for oral squamous cell carcinoma (OSCC) and is used to guide management. In this study, we aimed to identify an expression profile signature for ECS in node-positive OSCC using data derived from two different sources: a cohort of OSCC patients from our institution (National Cancer Centre Singapore) and The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma (HNSCC) cohort. We also sought to determine if this signature could serve as a prognostic factor in node negative cancers. Materials and methods: Patients with a histological diagnosis of OSCC were identified from an institutional database and fresh tumor samples were retrieved. RNA was extracted and gene expression profiling was performed using the Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray platform. RNA sequence data and corresponding clinical data for the TCGA HNSCC cohort were downloaded from the TCGA Data Portal. All data analyses were conducted using R package and SPSS. Results: We identified an 11 gene signature (GGH, MTFR1, CDKN3, PSRC1, SMIM3, CA9, IRX4, CPA3, ZSCAN16, CBX7 and ZFP3) which was robust in segregating tumors by ECS status. In node negative patients, patients harboring this ECS signature had a significantly worse overall survival (p = 0.04). Conclusions: An eleven gene signature for ECS was derived. Our results also suggest that this signature is prognostic in a separate subset of patients with no nodal metastasis Further validation of this signature on other datasets and immunohistochemical studies are required to establish utility of this signature in stratifying early stage OSCC patients. (C) 2014 Elsevier Ltd. All rights reserved.

Aim:To uncover the molecular mechanisms of early-onset ovarian serous cystadenocarcinoma (EOOSC; patients <50 years old) and late-onset ovarian serous cystadenocarcinoma (LOOSC; patients >= 50 years old).Materials & methods:Bioinformatics was utilized to identify the key factors.Results:478 EOOSC and 899 LOOSC individual differentially expressed genes were identified and enriched in different pathways. The expression of key genesLAG3,LRRC63andMT1Bsignificantly influenced the overall survival of EOOSC patients. The expression of key genesRDH12,NTSR1,ZSCAN16,CT45A3andEPPIN_WFDC6significantly affected the overall survival of LOOSC patients.Conclusions:The molecular mechanisms of EOOSC and LOOSC appear to be different, so that patients might be treated individually in respect of age. Lay abstract The chances of surviving ovarian cancer decrease as you get older. Ovarian serous cystadenocarcinoma is the most common and deadly type of ovarian cancer. Research has shown that there are differences between younger and older patients in relation to how the cancerous ovarian serous cystadenocarcinoma tumor behaves and how the body responds to the cancer. Our research is the first to show which genes could be responsible for these differences and which genes become more or less active as you grow older. Our results suggest that ovarian serous cystadenocarcinoma patients might need to be treated differently with respect to their ages.